Skip to main content

Advertisement

Table 2 Remission rate after infliximab induction therapy

From: Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe - a Hungarian nationwide observational study

Indication of IFX therapy Number and rate of remission
Overall 167 (46%)
Therapy-refractory CD by localization 45 (39.47%)
   Ileum 3/10 (30%)
   Colon 7/29 (24.13%)
   Ileo-colonic 29/46 (63.04%)
   Ileo-colonic and other small bowel 5/28 (17.85%)
   Oesophagus 1/1
Therapy-refractory and fistulizing 6 (37.5%)
Fistulizing 95 (48.71%)
   Perianal 72/148 (48.64%)
   Enterocutaneous 7/24 (29.16%)
   Enterovaginal 3/11
   Other 4/12
   Mixed 6/7
Steroid dependent 15 (57.69%)
   Ileum 3/3
   Colon 3/4
   Ileo-colic 9/19 (47.36%)
Metastatic 5 Na.
Other 1 Na.
  1. Na = not applicable